FDA gives green light to Regenerons Libtayo

FDA gives green light to Regeneron’s Libtayo

	pharmacy/fda-gives-green-light-to-regenerons-libtayo/"> The FDA has approved Regeneron’s Libtayo for metastatic cutaneous squamous cell carcinoma which is the second most common cancer in the United States. Read More

Original Article: FDA gives green light to Regeneron’s Libtayo

More From BioPortfolio on "FDA gives green light to Regeneron’s Libtayo"